The global wearable injectors market is likely to
grow from $2,162.1 million in 2015 to $13.0 billion by 2024. With the explosive
growth of bolus injectors and increasing interest of pharmaceutical companies in
collaborating with device manufacturers for drug device combination, the market
for wearable injectors is expected to show dramatic rise. The launch of bolus
injector expands the usage of wearable injectors from diabetes to other disease
segments, as the wearable injectors currently available in market are majorly
insulin pumps. The growing need for continuous and subcutaneous drug delivery
has developed the demand for wearable injectors among the patients.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/wearable-injectors-market/report-sample
Cancer is expected to be the largest application area of wearable injectors. According to the analyst, cancer and autoimmune disease are expected to be the major application areas for wearable injectors in the near future. The other key applications of wearable injectors include infectious disease, cardiovascular disease and blood disorders. Also, homecare is expected to be the largest end user of wearable injectors.
Increasing
need for better patient care is creating ample growth opportunities for the global
market. Electronic wearable injectors create yet another opportunity for the
global market, as these types of wearable injectors are technically more
advanced, do not require patient training and are easy to use. As
compared to these, mechanical wearable injectors are self-administration devices
that require one time administration of the drugs, manually, by the patient. Mechanical
wearable injectors are either pre-loaded or loaded at the time of
administration.
The research states that the global wearable injectors market had a consolidated structure in 2015, where the top three competitors accounted for the major share in the global wearable injectors market. Some of the key players operating in the global market are Becton, Dickinson and Company, Medtronic plc, Johnson & Johnson, F. Hoffmann-La Roche Ltd., Insulet Corporation, Unilife Corporation, CeQur SA, Enable Injections, ScPharmaceuticals, Inc., SteadyMed Ltd., Ypsomed Group, West Pharmaceutical Services, Inc. and Canè S.p.A.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/wearable-injectors-market/report-sample
Cancer is expected to be the largest application area of wearable injectors. According to the analyst, cancer and autoimmune disease are expected to be the major application areas for wearable injectors in the near future. The other key applications of wearable injectors include infectious disease, cardiovascular disease and blood disorders. Also, homecare is expected to be the largest end user of wearable injectors.
Growing need for advanced drug delivery is one of
the major factors driving the growth of the global wearable injectors market. Increasing
demand for homecare and advanced drug delivery requiring minimal expertise and
lesser hospitalization of patients is expected to drive the demand for wearable
injectors, globally. Also,
many biopharmaceutical companies have been looking for a better mode of drug
delivery for their portfolio of biologic drugs, for which wearable injectors
are an appropriate solution.
Access Report Overview: https://www.psmarketresearch.com/market-analysis/wearable-injectors-market
The research states that the global wearable injectors market had a consolidated structure in 2015, where the top three competitors accounted for the major share in the global wearable injectors market. Some of the key players operating in the global market are Becton, Dickinson and Company, Medtronic plc, Johnson & Johnson, F. Hoffmann-La Roche Ltd., Insulet Corporation, Unilife Corporation, CeQur SA, Enable Injections, ScPharmaceuticals, Inc., SteadyMed Ltd., Ypsomed Group, West Pharmaceutical Services, Inc. and Canè S.p.A.
No comments:
Post a Comment